{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T01:20:45Z","timestamp":1770513645788,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,6,30]],"date-time":"2014-06-30T00:00:00Z","timestamp":1404086400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["SpringerPlus"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/2193-1801-3-328","type":"journal-article","created":{"date-parts":[[2014,6,30]],"date-time":"2014-06-30T18:20:12Z","timestamp":1404152412000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Health resource utilization associated with skeletal-related events in patients with advanced breast cancer: results from a prospective, multinational observational study"],"prefix":"10.1186","volume":"3","author":[{"given":"Diana","family":"L\u00fcftner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Lorusso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guy","family":"Hechmati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Garzon-Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Ashcroft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Bahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prayashi","family":"Ghelani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Hoefeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,6,30]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"crossref","first-page":"693","DOI":"10.18553\/jmcp.2010.16.9.693","volume":"16","author":"A Barlev","year":"2010","unstructured":"Barlev A, Song X, Ivanov B, Setty V, Chung K: Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. J Manag Care Pharm 2010, 16: 693-702.","journal-title":"J Manag Care Pharm"},{"key":"1035_CR2","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","volume":"80","author":"RE Coleman","year":"1997","unstructured":"Coleman RE: Skeletal complications of malignancy. Cancer 1997, 80: 1588-1594. 10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","journal-title":"Cancer"},{"key":"1035_CR3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1053\/ctrv.2000.0210","volume":"27","author":"RE Coleman","year":"2001","unstructured":"Coleman RE: Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 2001, 27: 165-176. 10.1053\/ctrv.2000.0210","journal-title":"Cancer Treat Rev"},{"key":"1035_CR4","doi-asserted-by":"publisher","first-page":"6243s","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12: 6243s-6249s. 10.1158\/1078-0432.CCR-06-0931","journal-title":"Clin Cancer Res"},{"key":"1035_CR5","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","volume":"16","author":"L Costa","year":"2008","unstructured":"Costa L, Badia X, Chow E, Lipton A, Wardley A: Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence. Support Care Cancer 2008, 16: 879-889. 10.1007\/s00520-008-0418-0","journal-title":"Support Care Cancer"},{"key":"1035_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1097\/JTO.0b013e318206a1e3","volume":"6","author":"C Decroisette","year":"2011","unstructured":"Decroisette C, Monnet I, Berard H, Quere G, Le Caer H, Bota S, Audigier-Valette C, Geriniere L, Vernejoux JM, Chouaid C: Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol 2011, 6: 576-582. doi:10.1097\/JTO.0b013e318206a1e3","journal-title":"J Thorac Oncol"},{"key":"1035_CR7","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1159\/000082923","volume":"67","author":"T Delea","year":"2004","unstructured":"Delea T, Langer C, McKiernan J, Liss M, Edelsberg J, Brandman J, Sung J, Raut M, Oster G: The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Oncology 2004, 67: 390-396. 10.1159\/000082923","journal-title":"Oncology"},{"key":"1035_CR8","first-page":"341","volume":"4","author":"T Delea","year":"2006","unstructured":"Delea T, McKiernan J, Brandman J, Edelsberg J, Sung J, Raut M, Oster G: Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. J Support Oncol 2006, 4: 341-347.","journal-title":"J Support Oncol"},{"key":"1035_CR9","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-006-0203-x","volume":"15","author":"V DePuy","year":"2007","unstructured":"DePuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F: Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007, 15: 869-876. 10.1007\/s00520-006-0203-x","journal-title":"Support Care Cancer"},{"key":"1035_CR10","volume-title":"Denosumab (XGEVA) summary of product characteristics","author":"European Medicines Agency","year":"2012","unstructured":"European Medicines Agency: Denosumab (XGEVA) summary of product characteristics. 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002173\/WC500110381.pdf"},{"key":"1035_CR11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1748-717X-7-131","volume":"7","author":"J Exp\u00f3sito","year":"2012","unstructured":"Exp\u00f3sito J, Jaen J, Alonso E, Tovar I: Use of palliative radiotherapy in brain and bone metastases (VARA II study). Radiat Oncol 2012, 7: 131. doi:10.1186\/1748-717X-7-131","journal-title":"Radiat Oncol"},{"key":"1035_CR12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.jval.2010.11.014","volume":"14","author":"J Felix","year":"2011","unstructured":"Felix J, Andreozzi V, Soares M, Borrego P, Gervasio H, Moreira A, Costa L, Marcelo F, Peralta F, Furtado I, Pina F, Albuquerque C, Santos A, Passos-Coelho JL: Hospital resource utilization and treatment cost of skeletal-related events in patients with metastatic breast or prostate cancer: estimation for the Portuguese National Health System. Value Health 2011, 14: 499-505. doi:10.1016\/j.jval.2010.11.014","journal-title":"Value Health"},{"key":"1035_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","volume":"377","author":"K Fizazi","year":"2011","unstructured":"Fizazi K, Carducci M, Smith M, Dami\u00e3o R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C: Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011, 377: 813-822. 10.1016\/S0140-6736(10)62344-6","journal-title":"Lancet"},{"key":"1035_CR14","doi-asserted-by":"publisher","first-page":"A455","DOI":"10.1016\/j.jval.2011.08.1218","volume":"14","author":"O Gunther","year":"2011","unstructured":"Gunther O, Body JJ, Sleeboom H, Hechmati G, Pereira J, Maniadakis N, Terpos E, Acklin YP, Finek J, Mossman T, Von Moos R: Health resource utilisation (HRU) associated with skeletal-related events (SREs) in patients with bone metastases (BMS): results from a retrospective, multinational European study. Value Health 2011, 14: A455-A456. doi:10.1016\/j.jval.2011.08.1216","journal-title":"Value Health"},{"key":"1035_CR15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jval.2011.02.931","volume":"14","author":"G Hechmati","year":"2011","unstructured":"Hechmati G, Hoefeler H, Bahl A, L\u00fcftner D, Lorusso V, Garz\u00f3n Rodriguez C, Ashcroft J, Suenaert P, Wei R, Dur\u00e1n I: Skeletal-related events in patients with bone metastases lead to considerable health resource utilisation in Europe: analysis of a multinational observational study. Value Health 2011, 14: 168.","journal-title":"Value Health"},{"key":"1035_CR16","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","volume":"29","author":"DH Henry","year":"2011","unstructured":"Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H: Randomized, double-blind study of denosumab versus zoledronic Acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011, 29: 1125-1132. 10.1200\/JCO.2010.31.3304","journal-title":"J Clin Oncol"},{"key":"1035_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00402-001-0359-2","volume":"122","author":"A Katzer","year":"2002","unstructured":"Katzer A, Meenen NM, Grabbe F, Rueger JM: Surgery of skeletal metastases. Arch Orthop Trauma Surg 2002, 122: 251-258. 10.1007\/s00402-001-0359-2","journal-title":"Arch Orthop Trauma Surg"},{"key":"1035_CR18","first-page":"317","volume":"14","author":"MJ Lage","year":"2008","unstructured":"Lage MJ, Barber BL, Harrison DJ, Jun S: The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008, 14: 317-322.","journal-title":"Am J Manag Care"},{"key":"1035_CR19","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","volume":"88","author":"A Lipton","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN, Simeone J, Knight RD, Mellars K, Reitsma DJ, Heffernan M, Seaman JJ: Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88: 1082-1090. 10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","journal-title":"Cancer"},{"key":"1035_CR20","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.juro.2010.03.034","volume":"184","author":"M Norgaard","year":"2010","unstructured":"Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT: Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010, 184: 162-167. 10.1016\/j.juro.2010.03.034","journal-title":"J Urol"},{"key":"1035_CR21","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/j.1365-2354.2009.01135.x","volume":"19","author":"RD Pockett","year":"2010","unstructured":"Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K: The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl) 2010, 19: 755-760. doi:10.1111\/j.1365-2354.2009.01135.x","journal-title":"Eur J Cancer Care (Engl)"},{"key":"1035_CR22","volume-title":"Single fraction radiotherapy for bone metastases","author":"Royal College of Radiologists","year":"2007","unstructured":"Royal College of Radiologists: Single fraction radiotherapy for bone metastases. 2007. . Accessed 2 November 2012 http:\/\/www.rcr.ac.uk\/docs\/oncology\/pdf\/bonemetsreport.pdf"},{"key":"1035_CR23","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"F Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R: Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 2007, 110: 1860-1867. 10.1002\/cncr.22991","journal-title":"Cancer"},{"key":"1035_CR24","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/cncr.22678","volume":"109","author":"KL Schulman","year":"2007","unstructured":"Schulman KL, Kohles J: Economic burden of metastatic bone disease in the U.S. Cancer 2007, 109: 2334-2342. 10.1002\/cncr.22678","journal-title":"Cancer"},{"key":"1035_CR25","volume-title":"European Cancer Observatory: cancer incidence, mortality, prevalence and survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer","author":"E Steliarova-Foucher","year":"2012","unstructured":"Steliarova-Foucher E, O\u2019Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: cancer incidence, mortality, prevalence and survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. 2012. . Accessed 25 March 2013 http:\/\/eco.iarc.fr"},{"key":"1035_CR26","doi-asserted-by":"publisher","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","volume":"28","author":"AT Stopeck","year":"2010","unstructured":"Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer R, Lichinitser M, Fujiwara Y, Yardley D, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A, Investigators obotBCSS: Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010, 28: 5132-5139. 10.1200\/JCO.2010.29.7101","journal-title":"J Clin Oncol"},{"key":"1035_CR27","first-page":"97","volume":"5","author":"ML Svendsen","year":"2013","unstructured":"Svendsen ML, Gammelager H, Svaerke C, Yong M, Chia VM, Christiansen CF, Fryzek JP: Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark. Clin Epidemiol 2013, 5: 97-103. doi:10.2147\/CLEP.S42325 clep-5-097","journal-title":"Clin Epidemiol"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1136\/bmj.320.7243.1197","volume":"320","author":"SG Thompson","year":"2000","unstructured":"Thompson SG, Barber JA: How should cost data in pragmatic randomised trials be analysed? BMJ 2000, 320: 1197-1200. 10.1136\/bmj.320.7243.1197","journal-title":"BMJ"},{"key":"1035_CR29","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/01.mlr.0000108746.69256.45","volume":"42","author":"KP Weinfurt","year":"2004","unstructured":"Weinfurt KP, Castel LD, Li Y, Timbie JW, Glendenning GA, Schulman KA: Health-related quality of life among patients with breast cancer receiving zoledronic acid or pamidronate disodium for metastatic bone lesions. Med Care 2004, 42: 164-175. 10.1097\/01.mlr.0000108746.69256.45","journal-title":"Med Care"},{"key":"1035_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.clon.2007.03.011","volume":"19","author":"MV Williams","year":"2007","unstructured":"Williams MV, Summers ET, Drinkwater K, Barrett A: Radiotherapy dose fractionation, access and waiting times in the countries of the UK in 2005. Clin Oncol (R Coll Radiol) 2007, 19: 273-286. doi:10.1016\/j.clon.2007.03.011","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["SpringerPlus"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2193-1801-3-328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/2193-1801-3-328\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/2193-1801-3-328.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,10]],"date-time":"2022-04-10T00:28:33Z","timestamp":1649550513000},"score":1,"resource":{"primary":{"URL":"https:\/\/springerplus.springeropen.com\/articles\/10.1186\/2193-1801-3-328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,30]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1186\/2193-1801-3-328","relation":{},"ISSN":["2193-1801"],"issn-type":[{"value":"2193-1801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,30]]},"assertion":[{"value":"25 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"328"}}